Dr. Kretz-Rommel has more than 15 years of experience in discovering and developing antibodies for the treatment of cancer and autoimmune and inflammatory diseases. Prior to Anaphore, she led multiple discovery and development efforts as head of the Cellular Immunology group at Alexion Antibody Technologies and was a key investigator on a first-in-class drug currently in clinical trials for chronic lymphocytic leukemia, leading the program from discovery through preclinical modeling and pre-IND preparation. Dr. Kretz-Rommel received her post-doctoral training at the Autoimmune Disease Center of The Scripps Research Institute and holds a Ph.D. in Toxicology from the ETH Zurich, Switzerland. She is co-inventor or author on over fifty manuscripts, patents, patent applications and abstracts related to molecular pharmacology, autoimmune disease and oncology.
